| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/30/2011 | WO2011076930A1 Cyclic hydroxylamine derivatives, their preparation and use as antioxidants |
| 06/30/2011 | WO2011076854A1 CLEAVAGE OF β-AMYLOID PRECURSOR PROTEIN |
| 06/30/2011 | WO2011076812A1 Carboxamide compounds and their use as calpain inhibitors iv |
| 06/30/2011 | WO2011076811A1 Carboxamide compounds and their use as calpain inhibitors |
| 06/30/2011 | WO2011076747A1 Diaza-spiro[5.5]undecanes as orexin receptor antagonists |
| 06/30/2011 | WO2011076744A1 Disubstituted heteroaryl-fused pyridines |
| 06/30/2011 | WO2011076723A1 Amino-heteroaryl derivatives as hcn blockers |
| 06/30/2011 | WO2011076708A1 New aminotetraline derivatives |
| 06/30/2011 | WO2011076421A2 Compositions comprising venlafaxine and celecoxib in the treatment of pain |
| 06/30/2011 | WO2011076363A1 Morphinan-6-one compounds for the treatment or prevention of neurodegenerative diseases |
| 06/30/2011 | WO2011075943A1 Agomelatine and pharmaceutical compositions thereof |
| 06/30/2011 | WO2011075912A1 Pharmaceutical composition for treating parkinson's disease and preparation method thereof |
| 06/30/2011 | WO2011075777A1 Neuronal stimulation |
| 06/30/2011 | WO2011056240A3 Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| 06/30/2011 | WO2011034887A9 A method for treating neuropathic pain |
| 06/30/2011 | WO2011027257A3 Pcsk9 vaccine |
| 06/30/2011 | WO2011020030A3 Methods and compositions to prevent addiction |
| 06/30/2011 | WO2011014003A3 (+)-3-hydroxymorphinan derivatives as neuroprotectants |
| 06/30/2011 | WO2010132999A8 Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics |
| 06/30/2011 | WO2010113180A8 Antipsychotic agents and standardized antipsychotic fractions from rauwolfia tetraphylla and process of their isolation |
| 06/30/2011 | WO2010070023A3 Pharmaceutical orally deliverable formulations |
| 06/30/2011 | WO2010067010A3 Derivatives of morphine-6-glucuronide, preparation method thereof and use of same in therapeutics |
| 06/30/2011 | US20110162095 TNFSF Single Chain Molecules |
| 06/30/2011 | US20110160309 Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators |
| 06/30/2011 | US20110160305 Oral Delivery of Therapeutic Doses of Glutathione |
| 06/30/2011 | US20110160300 Renin Inhibitors and Methods of Use Thereof |
| 06/30/2011 | US20110160299 Composition and method |
| 06/30/2011 | US20110160296 Preparation of 6-oxa-8alpha-steroid estrogen analogues - a new group of unnatural estrogens and their use in medicine |
| 06/30/2011 | US20110160286 Allele-specific rna interference |
| 06/30/2011 | US20110160273 Co-crystals of duloxetine and cox-inhibitors for the treatment of pain |
| 06/30/2011 | US20110160272 Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy |
| 06/30/2011 | US20110160265 Method of treating motor disorders with alpha-2b adrenergic receptor agonists |
| 06/30/2011 | US20110160260 Method of Treating a Neurodegenerative Disorder |
| 06/30/2011 | US20110160253 Deuterated tizanidine |
| 06/30/2011 | US20110160248 Pyrazole compounds and uses thereof |
| 06/30/2011 | US20110160247 Aralkyl alcohol piperidine derivative and the use thereof as a medicament for treating depression |
| 06/30/2011 | US20110160246 Neurodegenerative Protein Aggregation Inhibition Methods and Compounds |
| 06/30/2011 | US20110160245 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| 06/30/2011 | US20110160244 Phenylpiperidine modulators of mu-opioid receptor |
| 06/30/2011 | US20110160243 Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
| 06/30/2011 | US20110160241 New peptidomimetic compounds |
| 06/30/2011 | US20110160239 Oral administration of peripherally-acting opioid antagonists |
| 06/30/2011 | US20110160235 Triazolyl tropane derivatives |
| 06/30/2011 | US20110160232 Certain chemical entities and therapeutic uses thereof |
| 06/30/2011 | US20110160229 Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia |
| 06/30/2011 | US20110160223 NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders |
| 06/30/2011 | US20110160220 Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| 06/30/2011 | US20110160215 Substituted Triazolo-Pyrazine Compounds |
| 06/30/2011 | US20110160208 Diaryl-substituted five-membered heterocycle derivative |
| 06/30/2011 | US20110160206 Tri-substituted pyrimidine compounds and their use as pde10 inhibitors |
| 06/30/2011 | US20110160205 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| 06/30/2011 | US20110160202 Pyrazine compounds as phosphodiesterase 10 inhibitors |
| 06/30/2011 | US20110160201 Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it |
| 06/30/2011 | US20110160199 Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia |
| 06/30/2011 | US20110160194 Anti-Inflammatory Analgesic External Preparation |
| 06/30/2011 | US20110160187 3-aryl-5,6-disubstituted pyridazines |
| 06/30/2011 | US20110160184 Dibenzothiazepine Derivatives and Use Thereof |
| 06/30/2011 | US20110160182 Pyrazine compounds as phosphodiesterase 10 inhibitors |
| 06/30/2011 | US20110160181 Substituted pyrazoline compounds, their preparation and use as medicaments |
| 06/30/2011 | US20110160180 Cannabinoid Receptor Ligands |
| 06/30/2011 | US20110160176 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 06/30/2011 | US20110160175 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer |
| 06/30/2011 | US20110160174 Method Of Treating Disorder Related To High Cholesterol Concentration |
| 06/30/2011 | US20110160164 Compounds for nonsense suppression and methods for their use |
| 06/30/2011 | US20110160163 INHIBITORS OF p38 |
| 06/30/2011 | US20110160161 Concentrated therapeutic phospholipid compositions |
| 06/30/2011 | US20110160158 Methods of treatment of bipolar disorder |
| 06/30/2011 | US20110160157 Methods of treating an inflammatory-related disease |
| 06/30/2011 | US20110160142 Alpha B-Crystallin as a therapy for inflammation |
| 06/30/2011 | US20110160141 Neurotrophic Peptides |
| 06/30/2011 | US20110160140 Composition for improving brain function and method for improving brain function |
| 06/30/2011 | US20110160139 Composition for improving brain function and method for improving brain function |
| 06/30/2011 | US20110160138 Composition for improving brain function and method for improving brain function |
| 06/30/2011 | US20110160119 Anti-inflammatory compounds and uses thereof |
| 06/30/2011 | US20110159129 Use of clerodendrum sp. for treating tic disorders or psychiatric disorders with sensorimotor gating deficits |
| 06/30/2011 | US20110159122 Combination of extracts of various plants for improving the symptoms of dementia disorders |
| 06/30/2011 | US20110159120 Synergistic anti-inflammatory compositions comprising boswellia serrata extracts |
| 06/30/2011 | US20110159098 Stabilization and delivery of nucleic acid complexes |
| 06/30/2011 | US20110159090 Abuse resistant drugs, method of use and method of making |
| 06/30/2011 | US20110159089 Abuse resistant drugs, method of use and method of making |
| 06/30/2011 | US20110159088 ORAL PHARMACEUTICAL FOR BASED ON AT LEAST ONE ACTIVE PRINCIPLE WHOSE SOLUBILITY VARIES AS A FUNCTION OF THE GASTRIC pH CONDITIONS |
| 06/30/2011 | US20110159083 Nanoparticles for protein drug delivery |
| 06/30/2011 | US20110159066 Methods For Treating Parkinson's Disease |
| 06/30/2011 | US20110159056 Methods and materials for stimulating proliferation of stem cells |
| 06/30/2011 | US20110159048 Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
| 06/30/2011 | US20110159046 Controlled release formulations exhibiting an ascending rate of release |
| 06/30/2011 | US20110159013 Anti-ADDL Antibodies and Uses Thereof |
| 06/30/2011 | US20110159012 Method for isolating neural cells using tenascin-r compounds |
| 06/30/2011 | US20110159007 Stable and soluble antibodies inhibiting tnf alpha |
| 06/30/2011 | US20110158992 Engineered Anti-IL-23R Antibodies |
| 06/30/2011 | US20110158986 Humanized antibodies that sequester amyloid beta peptide |
| 06/30/2011 | US20110158982 COMPOSITIONS AND METHODS FOR INHIBITING MAdCAM |
| 06/30/2011 | US20110158978 Ang-2 inhibition to treat multiple sclerosis |
| 06/30/2011 | US20110158969 Compositions and methods for using stromal cells to enhance treatment of central nervous system injuries |
| 06/30/2011 | US20110158968 Methods of making enhanced, autologous fat grafts |
| 06/30/2011 | US20110158967 Mesenchymal stem cell and the method of use thereof |
| 06/30/2011 | US20110158966 Stem cells characterized by expression of germline specific genes |
| 06/30/2011 | US20110158961 Materials and methods relating to cell based therapies |
| 06/30/2011 | US20110158956 Treating cancer |
| 06/30/2011 | US20110158907 Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques |